#Immunohistochemistry Market

[industrynewsupdates]

Key Trends Driving the Immunohistochemistry Market

The global immunohistochemistry (IHC) market was valued at USD 2.33 billion in 2022 and is projected to expand at a compound annual growth rate (CAGR) of 5.8% from 2023 to 2030. Several key factors are driving this market growth. One of the primary contributors is the increasing integration of automation and machine learning in immunohistochemistry, alongside the development and introduction of advanced IHC solutions. These technological advancements are expected to play a significant role in accelerating market growth throughout the forecast period.

In addition to technological improvements, advancements in IHC protocols have led to a notable rise in demand for these services, particularly in disease diagnosis. IHC is now an essential tool in diagnosing a variety of diseases, especially cancers, and its ability to identify specific biomarkers in tissue samples has made it indispensable in modern pathology. Furthermore, the growing number of product approvals and the introduction of next-generation immunohistochemistry systems are expected to provide additional momentum to the market.

Another emerging trend is the development and adoption of newer IHC techniques, such as multiplexed IHC. This approach allows for the simultaneous analysis of multiple biomarkers from a single tissue sample, providing a more comprehensive and detailed understanding of disease at the molecular level. Multiplexed IHC utilizes advanced methods like mass spectrometric detection, which addresses some of the technical limitations associated with traditional fluorescence-based detection methods. This innovation has contributed to increased market revenues by offering enhanced analytical capabilities for researchers and clinicians.

Gather more insights about the market drivers, restrains and growth of the Immunohistochemistry market

Regional Insights

The global immunohistochemistry (IHC) market is segmented by region into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. Among these regions, North America led the market in 2022, accounting for more than 38.39% of the total global revenue. Several factors have contributed to North America's dominance in the IHC market.

Key drivers include the presence of major market players within the region, which has fostered innovation and a competitive landscape, ensuring that IHC solutions are readily available and continually improved. Additionally, North American healthcare facilities and research institutions are quick to adopt advanced IHC technologies, leading to faster integration of cutting-edge tools in clinical and research settings. The region has also witnessed the launch of several new IHC solutions, further fueling market growth.

For example, in June 2021, PathAI, a U.S.-based developer specializing in AI-powered technology for pathology, showcased an innovative machine learning-based quality control tool specifically designed for HER2 testing in breast cancer. This tool was presented at the American Society of Clinical Oncology's Virtual Scientific Program, underscoring the region's emphasis on technological advancements that enhance diagnostic precision. Such innovations highlight the region's pivotal role in advancing the IHC field, particularly in the context of cancer diagnostics.

On the other hand, the Asia Pacific region is expected to experience the fastest growth in the IHC market over the forecast period. This rapid growth can be attributed to the increasing presence of global IHC companies expanding their operations in Asia, particularly in countries like India and China. These nations are seeing rising investments in healthcare infrastructure and the expansion of medical research, which contributes to the growing demand for IHC technologies.

Moreover, Asia's large and diverse patient population offers a significant advantage for conducting IHC research and development (R&D). Countries like India and China have a large number of clinical subjects available for IHC-based diagnostic assays, which drives the demand for more advanced immunohistochemistry solutions. This combination of factors – from the geographic expansion of global players to the large clinical subject pool in key countries – is expected to lead to a substantial increase in IHC market revenue in the Asia Pacific region.

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global plasma fractionation market size was estimated at USD 35.8 billion in 2024 and is projected to grow at a CAGR of 8.5% from 2025 to 2030.

• The global monoclonal antibodies market size was valued at USD 210.06 billion in 2022 and is projected to exhibit a compound annual growth rate (CAGR) of 11.04% from 2023 to 2030.

Key Companies & Market Share Insights

As demand for IHC assays, particularly in cancer diagnostics, continues to rise, leading companies in the field are taking various strategic actions to strengthen their positions in the market. These strategies include launching new products, forming mergers and acquisitions, and expanding their operations into new regional markets.

For example, in March 2023, Aptamer Group launched a new reagent solution called Optimer-Fc, designed specifically for use in automated immunohistochemistry workflows. This new solution is expected to open up new opportunities for the development of emerging biomarkers in diagnostics and research, thus helping to expand the company’s market reach.

Another notable development occurred in January 2021, when Abcam and Shuwen Biotech entered into a strategic alliance focused on developing and commercializing companion diagnostics (CDx). As part of the collaboration, Abcam is providing recombinant rabbit monoclonal antibodies to Shuwen Biotech, which will be used for further immunohistochemical verification. This partnership exemplifies how key market players are not only investing in product development but also in strategic collaborations to advance the application of IHC in personalized medicine and cancer diagnostics.

Some prominent players in the global immunohistochemistry market include:

• Thermo Fisher Scientific Inc.

• F. Hoffmann-La Roche Ltd.

• Merck KGaA

• Danaher Corporation

• Perkinelmer, Inc.

• Bio-Rad Laboratories, Inc.

• Cell Signaling Technology, Inc.

• Bio SB

• Agilent Technologies, Inc.

• Abcam plc.

Order a free sample PDF of the Immunohistochemistry Market Intelligence Study, published by Grand View Research.

[janetushar1]

Immunohistochemistry Market to Hit $3.7 Billion by 2032

The global Immunohistochemistry Market was valued at USD 2.1 Billion in 2024 and it is estimated to garner USD 3.7 Billion by 2032 with a registered CAGR of 8.6% during the forecast period 2024 to 2032.

The report throws light on the competitive scenario of the global Immunohistochemistry Market to know the competition at global levels. Market experts also provided the outline of each leading player of the global Immunohistochemistry Market for the market, considering the key aspects such as the areas of operation, production, and product portfolio. In addition, the companies in the report are studied based on vital factors such as company size, market share, market growth, revenue, production volume, and profit.

The global Immunohistochemistry Market is fragmented with various key players. Some of the key players identified across the value chain of the global Immunohistochemistry Market include Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Merck KGAA (Germany), Danaher Corporation (U.S.), PerkinElmer Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.) etc. Considering the increasing demand from global markets various new entries are expected in the Immunohistochemistry Market at regional as well as global levels.

Download Immunohistochemistry Market Sample Report PDF: https://www.vantagemarketresearch.com/immunohistochemistry-market-2132/request-sample

Top Competitors:

Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Merck KGAA (Germany), Danaher Corporation (U.S.), PerkinElmer Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.)

Understanding the Industry's Growth, has released an Updated report on the Immunohistochemistry Market. The report is mixed with crucial market insights that will support the clients to make the right business decisions. This research will help new players in the global Immunohistochemistry Market to sort out and study market needs, market size, and competition. The report provides information on the supply and market situation, the competitive situation and the challenges to the market growth, the market opportunities, and the threats faced by the major players.

Regional Analysis

-North America [United States, Canada, Mexico]

-South America [Brazil, Argentina, Columbia, Chile, Peru]

-Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]

-Middle East & Africa [GCC, North Africa, South Africa]

-Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]

You Can Buy This Report From Here: https://www.vantagemarketresearch.com/buy-now/immunohistochemistry-market-2132/0

Full Analysis Of The Immunohistochemistry Market:

Key findings and recommendations point to vital progressive industry trends in the global Immunohistochemistry Market, empowering players to improve effective long-term policies.

The report makes a full analysis of the factors driving the development of the market.

Analyzing the market opportunities for stakeholders by categorizing the high-growth divisions of the market.

Questions answered in the report

-Who are the top five players in the global Immunohistochemistry Market?

-How will the global Immunohistochemistry Market change in the next five years?

-Which product and application will take the lion's share of the global Immunohistochemistry Market?

-What are the drivers and restraints of the global Immunohistochemistry Market?

-Which regional market will show the highest growth?

-What will be the CAGR and size of the global Immunohistochemistry Market during the forecast period?

Read Full Research Report with [TOC] @ https://www.vantagemarketresearch.com/industry-report/immunohistochemistry-market-2132

Reasons to Purchase this Immunohistochemistry Market Report:

-Analysis of the market outlook on current trends and SWOT analysis.

-The geographic and country level is designed to integrate the supply and demand organizations that drive industry growth.

-Immunohistochemistry Industry dynamics along with market growth opportunities in the coming years.

-Immunohistochemistry Market value (million USD) and volume (million units) data for each segment and sub-segment.

1 year consulting for analysts along with development data support in Excel. Competitive landscape including market share of major players along with various projects and strategies adopted by players in the last five years.

Market segmentation analysis including qualitative and quantitative analysis including the impact on financial and non-economic aspects.

Complete company profiles that include performance presentations, key financial overviews, current developments, SWOT analyzes and strategies used by major Immunohistochemistry Market players.

Check Out More Reports

Global Meningococcal Vaccines Market:  Report Forecast by 2032

Global Baby Food Market: Report Forecast by 2032

Global IP Core & Edge Routers and Switches Market: Report Forecast by 2032

Global Edutainment Market: Report Forecast by 2032

Global U.S. Eubiotics Market: Report Forecast by 2032

[marketreports-blog]

The global Immunohistochemistry market size was valued at USD 3.19 billion in 2023 and is poised to exceed USD 5.66 billion by 2033, expanding at a CAGR of 5.9% between 2024 and 2033. North America dominated the market in 2023 and accounted for the largest share of more than 40.12%.

[psychicsheeparcade]

Immunohistochemistry Business Growth, Development Factors, Current and Future Trends till 2034.

The Global Immunohistochemistry Market is expected to reach USD 7.95 billion in 2034, based on an average growth pattern, and the report projects that the market will grow at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2034. Revenue from the global immunohistochemistry market is projected to reach USD 3.68 billion by 2024.

Immunohistochemistry (IHC) is a pivotal technique in histology and immunology that involves the detection of antigens in biological tissues. Using labeled antibodies, IHC provides invaluable insights for diagnostic, therapeutic, and research purposes. Over the years, this field has witnessed robust advancements, making it a cornerstone in personalized medicine and translational research.

Get a Sample Copy of Report, Click Here@  https://wemarketresearch.com/reports/request-free-sample-pdf/immunohistochemistry-market/1595

Immunohistochemistry Market Drivers

Increasing Cancer Prevalence:

According to the World Health Organization (WHO), cancer is one of the leading causes of mortality worldwide, with an estimated 10 million deaths in 2020.

IHC is instrumental in identifying cancer biomarkers like HER2, ER/PR, and Ki-67, which guide treatment decisions.

Emergence of Targeted Therapy:

The shift towards precision medicine has fueled demand for IHC in identifying predictive and prognostic markers for diseases.

Companion diagnostics, especially for immunotherapies and targeted drugs, heavily rely on IHC.

Advancements in Automation:

The development of automated IHC platforms such as Ventana (Roche) and Benchmark Ultra has revolutionized workflows, reducing human error and increasing reproducibility.

Applications in Neuroscience and Infectious Diseases:

Beyond oncology, IHC is being used to study neurodegenerative disorders (e.g., Alzheimer's, Parkinson's) and infectious diseases, including HIV and COVID-19-related complication

Emerging Trends in the Market

Multiplex IHC:

Multiplexing enables the simultaneous detection of multiple biomarkers within a single tissue sample, enhancing diagnostic accuracy in complex diseases.

This approach is becoming increasingly popular in research settings, especially for immuno-oncology studies.

Integration with Digital Pathology and AI:

AI-powered tools are being integrated with digital pathology systems to assist pathologists in interpreting IHC slides with greater precision.

AI algorithms can quantify marker expression and identify patterns missed by the human eye.

Advent of Novel Biomarkers:

Research is driving the discovery of new biomarkers for diseases like lung cancer, autoimmune disorders, and cardiovascular diseases.

These biomarkers are increasing the demand for specific IHC reagents and kits.

Immunohistochemistry Market Challenges 

High Cost of Instruments and Reagents:

Automated systems and high-quality reagents remain expensive, limiting their adoption in low-income regions.

Lack of Skilled Professionals:

Accurate interpretation of IHC results requires extensive training, which is a barrier in under-resourced settings.

Regulatory Constraints:

Diagnostic products, especially those used in companion diagnostics, face stringent regulations, delaying their approval and market entry.

Immunohistochemistry Market Opportunities for Growth

Expansion in Emerging Markets: Governments in countries like India and China are investing in healthcare infrastructure, opening new opportunities for IHC companies.

Customizable IHC Solutions:  Demand for tailor-made antibodies and reagents is growing as research expands into niche areas.

Partnerships and Collaborations: Companies are forming strategic alliances to accelerate research and development, ensuring quicker market penetration.

Immunohistochemistry Market Segments

By Product

Antibodies

Kits

REAGENTS

By End-User

Hospitals

Academic

Diagnostic Labs

By Application

Forensic

Diagnostic

Research

Immunohistochemistry Key  Market Players 

The Immunohistochemistry Market is dominated by a few large companies, such as

F. Hoffmann-La Roche Ltd

Agilent Technologies, Inc.

Danaher Corporation (Leica Biosystems)

Thermo Fisher Scientific Inc.

Merck KGaA (MilliporeSigma)

Bio-Rad Laboratories, Inc.

Abcam plc

Biocare Medical, LLC

Cell Signaling Technology, Inc. (CST)

PerkinElmer Inc.

Sakura Finetek Japan Co., Ltd.

Becton, Dickinson and Company (BD)

Immunohistochemistry Industry: Regional Analysis

 North American market's forecast

North America is the world's largest market, with more than 38% of the worldwide market in 2023. Among the factors contributing to the region's dominance include a stable healthcare system, the presence of significant market participants, an emphasis on cancer research and individualized treatment, and the widespread application of state-of-the-art diagnostic techniques. The United States and Canada are the two countries that contribute the most to this industry.  

Asia-Pacific Market Forecasts

Growing demand for individualized treatment, increased knowledge of early cancer detection, and increased spending in healthcare infrastructure are the main drivers of growth in this area. Leading contributors to the regional market include South Korea, Japan, China, and India. There are many potential for the market to grow in this area due to the growing number of pharmaceutical and biotechnology businesses as well as the availability of a big patient pool.

Market Statistics for Europe

The market is expanding in this region due to a number of factors, including the growing incidence of chronic illnesses, rising healthcare costs, and a strong focus on research and development in nations like Germany, France, and the UK. The growth of the IHC market in Europe is further supported by the existence of advantageous reimbursement and regulatory frameworks.

FAQs on the Immunohistochemistry (IHC) Market

1.What is Immunohistochemistry (IHC)?

2. What factors are driving the growth of the IHC market?

3. Which regions are leading the IHC market?

4.What are the major market segments in IHC?

[global-research-report]

Global Demand for Recombinant Proteins: Market Analysis and Forecast

The global recombinant proteins market size is expected to reach USD 5.58 billion in 2030 and is projected to grow at a CAGR of 10.2% from 2025 to 2030. Diseases like multiple sclerosis, neutropenia, cerebral apoplexy, anemia, and others, as well as dwarfism, are becoming more common, which is driving up the demand for recombinant protein drugs. Furthermore, the industry is anticipated to expand due to the increased development and research on biologics, which, in turn, are significantly boosting global industry growth. The focus on the development of biosimilars, biologics, and recombinant proteins has increased owing to a rise in the incidence and prevalence of cancer and the expansion of research & development activity.

According to the American Cancer Society, in 2022, there will be 1.9 million new cancer cases and 609,360 cancer-related deaths. In addition, the expanding application of recombinant proteins in clinical diagnostic methods including ELISA, Western Blotting, and Immunohistochemistry (IHC) is anticipated to fuel market expansion. Due to factors including rising R&D spending, an increase in the number of cancer patients, and the desire for novel & tailored therapies, the global industry is anticipated to expand significantly during the forecast period. Research activity in recombinant protein space has increased in response to the COVID-19 pandemic as a result of efforts to comprehend the dynamics of the virus. The production of recombinant proteins has increased significantly, along with tailored treatment.

In addition, research funding is predicted to become more readily available along with an increase in demand for and production of recombinant proteins, particularly those immune response proteins associated with COVID-19. Therefore, positive effects have been seen for the companies offering products specifically made for COVID-19. Recombinant protein is viewed as a modified version of natural protein that can be produced in a number of ways to improve protein output, create useful commercial goods, and alter gene sequences. The main drivers of the global industry are the rise in pharmaceutical firms’ R&D expenditures, high incidence of chronic illnesses, an increase in the number of regulatory requirements, and the ongoing need to reduce viral infections.

Over the projected period, the global industry is anticipated to be driven by technological advancements in the synthesis of recombinant proteins. For instance, in June 2022, according to the data produced by the National Center for Biotechnology Information, new breeding techniques, such as CRISPR/Cas9, TALEN, and Zinc Finger mediated, as well as transgenic or cis-genic techniques, are emerging technologies that may make it easier for in vitro genetic editing or manipulation of the genes to be approved. In addition, industry participants are anticipated to invest in the region due to the aging population, rising income levels, better healthcare infrastructure, rising healthcare spending, and the advantages of low-cost manufacturing in developing nations, thereby propelling market growth.

Recombinant Proteins Market Report Highlights

The cytokines & growth factors segment held the largest share of 24.6% of the market in 2024. This segment is anticipated to grow exponentially throughout the forecast period.

The therapeutics segment dominated the global market with a share of 34.2% in 2024 due to the prevalence of various diseases, such as metabolic disorders, cancer, genetic disorders, and immune diseases.

The pharma & biotechnology companies segment captured the largest market share of 38.1% in 2024. The inclination towards biologics and biosimilars has resulted in a cascade of multi-million investments by bio-manufacturers in R&D to grow the pipeline of products, devise new technologies, and advance bioprocessing tools.

The mammalian segment held the largest revenue share of 42.1% of the recombinant proteins market in 2024.

North America was the dominant region in 2024 due to an increase in the incidence of chronic diseases, use of cutting-edge treatments, the presence of key players, and a rise in healthcare spending in the region.

Recombinant Proteins Market Segmentation

Grand View Research has segmented the global recombinant proteins market based on product, application, end use, host cell, and region:

Recombinant Proteins Product Outlook (Revenue, USD Million, 2018 - 2030)

Cytokines & Growth Factors

Interferons (IFNs)

Interleukins (ILs)

Others

Antibodies

Immune checkpoint proteins

Virus Antigens

Enzymes

Kinases

Metabolic enzymes

Others

Recombinant Regulatory Protein

Hormones

Others

Recombinant Proteins Application Outlook (Revenue, USD Million, 2018 - 2030)

Drug Discovery & Development

Therapeutics

Biologics

Vaccines

Cell & Gene Therapies

Others

Research

Others

Recombinant Proteins End Use Outlook (Revenue, USD Million, 2018 - 2030)

Pharma & Biotechnology Companies

Academic & Research Institutes

Diagnostic Laboratories

Others

Recombinant Proteins Host Cell Outlook (Revenue, USD Million, 2018 - 2030)

Mammalian systems

Insect Cells

Yeast & Fungi

Bacterial Cells

Others

Recombinant Proteins Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

US

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

Latin America

Brazil

Argentina

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

List of Key Players

Sino Biological, Inc.

Bio-Techne

GenScript

Bio-Rad Laboratories, Inc.

Merck KGaA

Thermo Fisher Scientific

Proteintech Group, Inc.

Enzo Life Sciences, Inc. 

Abnova Corporation

RayBiotech Life Inc.

STEMCELL Technologies Inc.

Order a free sample PDF of the Recombinant Proteins Market Intelligence Study, published by Grand View Research.

[navyasri1]

Immunohistochemistry Market - Forecast(2024 - 2030)

Immunohistochemistry (IHC) can be defined as the process of selectively imaging antigens such as proteins in cells of a tissue section by exploiting the principle of antibodies binding specifically to antigens in biological tissues. This process is mainly used for the detection of abnormal cells such as cancerous cells in the tissue. Globally increasing awareness about cancer and developing healthcare infrastructure in emerging economies is expected to remain key growth driver during the period of study.

[lovelypol]

Precision Diagnostics Market Surge: $57.5B in 2023 to $157.2B by 2033 (10.5% CAGR)

Precision Diagnostics Market focuses on advanced technologies and methodologies designed to enhance the accuracy of disease detection and support personalized healthcare solutions. This includes molecular diagnostics, imaging technologies, and bioinformatics tools that enable early, precise diagnosis, tailored treatment planning, and ongoing monitoring. The market plays a vital role in the shift toward personalized medicine, which improves patient outcomes and optimizes healthcare resources by offering individualized diagnostic solutions.

To Request Sample Report: https://www.globalinsightservices.com/request-sample/?id=GIS22118 &utm_source=SnehaPatil&utm_medium=Article

Market Growth and Trends

The Precision Diagnostics Market is experiencing robust growth, driven by advancements in molecular diagnostics and imaging technologies. Among the sub-segments, molecular diagnostics lead the market due to their pivotal role in personalized healthcare and early disease detection. Next-generation sequencing (NGS) is the top performer within this segment, thanks to its precision, growing accessibility, and declining costs. Imaging diagnostics, particularly MRI and CT scans, also represent a significant segment, benefitting from ongoing technological advancements and rising healthcare expenditure.

Regional Insights

North America dominates the market, fueled by a strong healthcare infrastructure, substantial R&D investments, and a high adoption rate of innovative diagnostic technologies. The United States is the leading country, driven by advanced healthcare facilities and widespread implementation of precision diagnostics.

Europe ranks second, with Germany and the United Kingdom emerging as key contributors, spurred by increasing demand for early disease diagnosis and precise medical interventions.

Asia-Pacific is rapidly growing, with China and India seeing significant market expansion. The region’s growth is driven by increasing healthcare awareness, rising income levels, and improved access to diagnostic technologies.

Market Segmentation

By Type: Genetic Testing, Molecular Diagnostics, Companion Diagnostics, Point-of-Care Testing, Liquid Biopsy By Product: Reagents & Kits, Instruments, Software & Services, Consumables By Technology: Next-Generation Sequencing, Polymerase Chain Reaction, Fluorescence In Situ Hybridization, Immunohistochemistry, Microarray By Application: Oncology, Cardiology, Infectious Diseases, Neurology, Endocrinology By End User: Hospitals, Diagnostic Laboratories, Research Institutes, Academic Institutes By Component: Hardware, Software, Services By Device: Benchtop, Portable, Handheld, Wearable By Process: Sample Preparation, Data Analysis, Validation By Deployment: On-Premise, Cloud-Based, Hybrid By Solutions: Clinical Decision Support, Data Management, Patient Engagement

Market Volume & Projections

In 2023, the market demonstrated a strong volume of 320 million diagnostic tests globally, with projections indicating a rise to 520 million tests by 2033. The molecular diagnostics segment commands a substantial 45% market share, followed by genetic testing at 30%, and imaging diagnostics at 25%. This market dominance is driven by advancements in genomics and a growing demand for personalized medicine.

Key Market Players

Leading players in the Precision Diagnostics Market include Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific, which continue to influence the market through cutting-edge technology, strategic partnerships, and ongoing innovation to maintain their competitive edge.

#PrecisionDiagnostics #PersonalizedHealthcare #MolecularDiagnostics #GeneticTesting #NextGenerationSequencing #Oncology #Cardiology #EarlyDiagnosis #HealthcareInnovation #ImagingTechnologies #LiquidBiopsy #Bioinformatics #MedicalDevices #HealthcareSolutions #DiagnosticReagents

[kristinahertzz]

Protein Detection Quantification Market

Protein Detection Quantification Market Size, Share, Trends: Thermo Fisher Scientific Inc. Leads

Shift Towards Multiplex Protein Detection and Quantification Technologies for Comprehensive Proteome Analysis

Market Overview:

The Protein Detection Quantification Market is projected to grow at a CAGR of 6.5% from 2024 to 2031, reaching a value of USD 3.8 billion by 2031. North America dominates the market, accounting for a significant share of the global market.

Key metrics driving this growth include increasing R&D activities in proteomics and the rising prevalence of chronic diseases. The protein detection quantification market is expanding rapidly, owing to advances in proteomic technology and a growing emphasis on personalised therapy. The integration of artificial intelligence and machine learning into protein analysis instruments improves accuracy and efficiency, thus pushing market growth. 

DOWNLOAD FREE SAMPLE

Market Trends:

The protein detection quantification market is witnessing a significant shift towards multiplex technologies that allow simultaneous detection and quantification of multiple proteins. This trend is driven by the growing demand for comprehensive proteome analysis in various research and clinical applications. Multiplex assays offer advantages such as reduced sample volume requirements, increased throughput, and cost-effectiveness.

In 2023, the multiplex protein detection segment accounted for a substantial market share, with a projected CAGR of 7.2% from 2024 to 2031. This growth is fueled by the increasing adoption of multiplex technologies in drug discovery and biomarker identification processes. Recent industry developments include the launch of advanced multiplex protein detection platforms. For instance, a leading life sciences company introduced a high-plex protein detection system in 2023, capable of analyzing up to 1,000 proteins simultaneously from a single sample, catering to the growing demand for large-scale proteomics studies.

Market Segmentation:

Immunological methods dominate the protein detection quantification market, accounting for a significant portion of the global market share. Immunological approaches have emerged as the leading technology in the protein detection quantification industry, due to their high specificity, sensitivity, and versatility in identifying and measuring a diverse spectrum of proteins across multiple sample types.

Immunological procedures, such as enzyme-linked immunosorbent tests (ELISA), Western blotting, and immunohistochemistry, offer various benefits, including ease of use, quick findings, and the capacity to detect low-abundance proteins. Over the last two years, immunological approaches have experienced a 15% increase in use in the pharmaceutical and biotechnology industries. Recent advances in immunological approaches have centered on increasing sensitivity and multiplexing abilities. A leading manufacturer has launched a novel multiplexed immunoassay technology that can quantify up to 100 proteins from a single sample with femtogram-level sensitivity.

Market Key Players:

Prominent players in the protein detection quantification market include Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Merck KGaA, PerkinElmer, Inc., Abcam plc, Becton, Dickinson and Company, Cell Signaling Technology, Inc., Promega Corporation, Qiagen N.V., Agilent Technologies, Inc., Quanterix Corporation, and Olink Proteomics AB. These companies are leading the market with their innovative approaches, extensive product portfolios, and robust distribution networks, continuously setting industry standards and driving market growth.

Contact Us:

Name: Hari Krishna

Email us: hari.krishna@aurorawaveintellects.com

Website: https://aurorawaveintellects.com/

[industrynewsupdates]

Future of Immunohistochemistry Market: What to Expect

The global immunohistochemistry (IHC) market was valued at USD 2.33 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 5.8% from 2023 to 2030. This growth is driven by several key factors, including the increasing implementation of automation and machine learning technologies in immunohistochemistry, as well as the continuous introduction of advanced, cutting-edge IHC solutions. These innovations are expected to substantially fuel the market's expansion throughout the forecast period. Additionally, improvements in IHC protocols have led to a significant rise in its demand, especially for disease diagnosis. The approval and launch of more advanced IHC systems for disease detection are also major contributors to the market’s upward trajectory.

Emerging techniques like multiplexed IHC, which enables multiparametric and detailed analysis from a single tissue sample using advanced mass spectrometric detection methods, are playing a crucial role in driving the market. Multiplexed IHC overcomes the challenges associated with fluorescence detection-based methods, thus contributing to an increase in market revenue. Furthermore, the growing elderly population in both developed and emerging countries is expected to positively influence the immunohistochemistry market. As the global geriatric population increases, the prevalence of age-related diseases is also anticipated to rise, which will further stimulate the demand for IHC technologies.

For example, during the COVID-19 pandemic, IHC methods, along with RT-PCR and electron microscopy, were used to detect SARS-CoV-2, revealing that the impact of the virus extends beyond just the lungs. This underscores the expanding role of IHC in diagnosing a broader range of conditions.

Gather more insights about the market drivers, restrains and growth of the Immunohistochemistry Market

Application Insights

The immunohistochemistry market is categorized into two primary application segments: diagnostics and research. The diagnostics segment held the largest revenue share, accounting for more than 69.16% in 2022, and is expected to maintain its dominance over the forecast period. Immunohistochemistry is widely utilized in diagnosing various chronic diseases, including cancer, cardiovascular diseases, infectious diseases, diabetes, autoimmune disorders, and nephrological diseases. The increasing prevalence of these chronic conditions is anticipated to further boost the demand for IHC-based diagnostic applications.

For instance, according to data from the American Cancer Society, approximately 1.9 million new cancer cases were expected to be diagnosed in the U.S. in 2021. As the number of cancer diagnoses continues to rise, the demand for IHC techniques that provide rapid, accurate, and efficient diagnosis is growing. This increased demand for IHC is further fueled by the rising levels of research and development (R&D) activities in the pharmaceutical sector. Pharmaceutical companies are focusing on developing new and innovative drugs, which will drive the demand for advanced IHC solutions.

An example of this growing focus on innovation is NHS England's announcement in July 2021 of a novel Innovative Medicines Fund, aimed at accelerating the development of new drugs. This initiative is expected to contribute to the overall expansion of the immunohistochemistry market by promoting the use of IHC in both research and clinical settings.

Order a free sample PDF of the Immunohistochemistry Market Intelligence Study, published by Grand View Research.

[credenceresearchdotblog]

The global Cell Surface Markers Market is poised for significant growth, with projections estimating an increase from USD 5,450 million in 2024 to USD 10,405.71 million by 2032, reflecting a compound annual growth rate (CAGR) of 8.42% over the forecast period. The global cell surface markers market has emerged as a cornerstone in biomedical research, diagnostics, and therapeutics. Cell surface markers—specific proteins or antigens present on the surface of cells—are critical in identifying and categorizing cell types, understanding immune responses, and diagnosing diseases. The market has witnessed robust growth due to advances in technologies such as flow cytometry, increasing research and development activities, and a surge in demand for precision medicine.

Browse the full report at https://www.credenceresearch.com/report/cell-surface-markers-market

Market Overview

The cell surface markers market encompasses instruments, reagents, and services used in research and clinical applications. The market is broadly segmented by product type, application, end-user, and geography. Key technologies driving the market include flow cytometry, immunohistochemistry, and mass spectrometry.

In terms of applications, the market is dominated by research on immunology and oncology. Immunological studies leverage cell surface markers to understand immune responses, while oncology research focuses on identifying tumor-specific markers for targeted therapies. The clinical diagnostics segment, particularly in hematology and autoimmune diseases, is also expanding rapidly.

Key Drivers of Market Growth

Rising Prevalence of Chronic Diseases Chronic diseases, such as cancer, diabetes, and autoimmune disorders, have seen a significant increase globally. This has heightened the demand for diagnostic tools and personalized medicine, where cell surface markers play a pivotal role. For example, CD markers are extensively used in diagnosing leukemias and lymphomas.

Technological Advancements Innovations in flow cytometry and mass spectrometry have revolutionized the analysis of cell surface markers, enabling higher accuracy, sensitivity, and throughput. Multicolor flow cytometry, for instance, allows the simultaneous analysis of multiple markers, facilitating comprehensive immunophenotyping.

Growing Investment in Research Governments and private organizations are increasingly funding life sciences research. This includes studies on cellular mechanisms, immune profiling, and cancer biology, all of which rely heavily on cell surface marker technologies.

Personalized Medicine and Immunotherapy The shift towards personalized medicine, particularly in oncology and autoimmune diseases, has amplified the importance of cell surface markers. These markers are critical in identifying patients who are most likely to respond to specific therapies, such as CAR-T cell therapy.

Market Challenges

Despite the growth prospects, the market faces several challenges:

High Costs of Instruments and Reagents: Advanced technologies like flow cytometers and their associated reagents are expensive, limiting accessibility, especially in developing regions.

Technical Complexity: The need for specialized expertise to operate instruments and analyze data remains a significant barrier.

Stringent Regulatory Requirements: The development and approval process for diagnostics and therapeutic applications involving cell surface markers is time-consuming and complex.

Future Outlook

The cell surface markers market is poised for significant growth, with a projected compound annual growth rate (CAGR) of over 8% during the forecast period (2023-2030). Key trends shaping the future of the market include:

Integration with Artificial Intelligence: AI-driven tools for data analysis are expected to enhance the accuracy and efficiency of cell surface marker studies.

Expansion of Applications: Beyond immunology and oncology, there is increasing interest in using cell surface markers in neurology, infectious diseases, and regenerative medicine.

Focus on Emerging Markets: Companies are likely to expand their footprint in emerging economies, leveraging local partnerships and tailored product offerings.

Key Player Analysis:

Becton, Dickinson and Company (BD)

Thermo Fisher Scientific, Inc.

Danaher Corporation

Merck KGaA

Bio-Rad Laboratories, Inc.

Agilent Technologies, Inc.

Miltenyi Biotec

Abcam PLC

Cell Signaling Technology, Inc.

Beckman Coulter, Inc.

Segmentations:

By Product

antibodies and PCR Arrays

mice

rats

other sources

By cell type

monocyte cell surface markers

NK cell surface markers

T cell surface markers

B cell surface markers

other cell types.

By application

research applications

clinical applications.

By end-user

hospitals & clinical testing laboratories

academic & research institutes

pharmaceutical & biotechnology companies.

Regional

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/cell-surface-markers-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

[psychicsheeparcade]

Immunohistochemistry Market Share, Size, Demand, Key Players by Forecast 2034

The Immunohistochemistry (IHC) market is a rapidly growing segment in the field of life sciences, driven by advancements in diagnostic techniques, increasing prevalence of chronic diseases, and rising demand for personalized medicine. IHC is a technique used to detect specific antigens in tissue samples by employing antibodies, enabling researchers and clinicians to gain insights into disease mechanisms, tumor classification, and therapeutic targets.

The global immunohistochemistry market is expected to reach USD 7.95 billion in 2034 based on average growth. Additionally, the analysis projects that between 2024 and 2034, the market would expand at a compound annual growth rate (CAGR) of 7.5%. It is projected that the worldwide immunohistochemistry industry would bring in USD 3.68 billion by 2024. 

Get a Sample Copy of Report, Click Here@  https://wemarketresearch.com/reports/request-free-sample-pdf/immunohistochemistry-market/1595

Immunohistochemistry Market Drivers

Rising Incidence of Cancer: IHC plays a pivotal role in cancer diagnosis and prognosis by providing insights into tumor origin and progression. The increasing prevalence of cancer globally is a significant driver for the market.

Advancements in Diagnostic Techniques: Technological advancements, such as automated staining systems and digital pathology, have improved the accuracy and efficiency of IHC, making it a preferred diagnostic tool.

Growth in Personalized Medicine: IHC is extensively used to determine biomarker expression levels, aiding in targeted therapies and personalized treatment plans.

Expansion of Healthcare Infrastructure: Emerging markets are witnessing significant investments in healthcare infrastructure, leading to greater adoption of advanced diagnostic tools like IHC.

Immunohistochemistry  Market Challenges

High Costs of IHC Instruments and Reagents: The cost of setting up IHC labs and procuring antibodies and reagents can be prohibitive, especially for smaller healthcare facilities.

Limited Skilled Workforce: Performing IHC tests requires expertise, and the shortage of trained professionals can hinder market growth.

Immunohistochemistry Market Opportunities

Growth in Emerging Markets: Developing countries in Asia-Pacific and Latin America are investing heavily in healthcare, creating lucrative opportunities for IHC manufacturers.

Integration with Artificial Intelligence (AI): AI-powered image analysis tools are being integrated with IHC to enhance diagnostic precision and reduce human error.

Emerging Trends in the IHC Market

Multiplex Immunohistochemistry (mIHC):

Enables simultaneous detection of multiple biomarkers within a single tissue sample, offering deeper insights into complex diseases like cancer and immune disorders.

Growing demand in immuno-oncology research and drug development.

Integration of Digital Pathology:

Adoption of whole-slide imaging and AI-powered diagnostic solutions to enhance workflow efficiency and diagnostic accuracy.

Facilitates remote consultations and second opinions through telepathology.

Companion Diagnostics:

Growing use of IHC in companion diagnostics to identify patients likely to benefit from specific therapies, particularly in oncology.

Examples include HER2 testing in breast cancer and PD-L1 testing in immunotherapy.

Automated Systems and Robotics:

Increasing use of automated staining platforms for faster processing and reduced manual errors.

Innovations like on-board reagent management systems to enhance lab productivity.

Emergence of Novel Biomarkers:

Identification of new biomarkers for complex diseases, expanding the scope of IHC applications.

Significant focus on immune checkpoint biomarkers such as CTLA-4 and LAG-3.

Immunohistochemistry Key  Market Players 

The Immunohistochemistry Market is dominated by a few large companies, such as

F. Hoffmann-La Roche Ltd

Agilent Technologies, Inc.

Danaher Corporation (Leica Biosystems)

Thermo Fisher Scientific Inc.

Merck KGaA (MilliporeSigma)

Bio-Rad Laboratories, Inc.

Abcam plc

Biocare Medical, LLC

Cell Signaling Technology, Inc. (CST)

PerkinElmer Inc.

Sakura Finetek Japan Co., Ltd.

Becton, Dickinson and Company (BD)

Immunohistochemistry Market Segments

By Product

Antibodies

Kits

REAGENTS

By End-User

Hospitals

Academic

Diagnostic Labs

By Application

Forensic

Diagnostic

Research

Immunohistochemistry Industry: Regional Analysis

 North American market's forecast

North America was the largest market in the world in 2023, with more than 38% of the worldwide market. The region's supremacy is attributed to a number of factors, including a stable healthcare system, the presence of significant market participants, a strong emphasis on cancer research and individualized treatment, and the widespread use of state-of-the-art diagnostic techniques. The United States and Canada are the two countries that provide the largest contributions to this industry.  

Asia-Pacific Market Forecasts

Increased investment in healthcare infrastructure, a growing demand for individualized care, and growing awareness of early cancer detection are the primary drivers of growth in this field. The leading contributors to the regional market are South Korea, Japan, India, and China. The huge patient base and the increasing number of pharmaceutical and biotechnology companies in this sector present numerous opportunities for market growth.    

Market Statistics for Europe

The market is growing in this sector due to a number of factors, including rising healthcare expenses, the incidence of chronic illnesses, and a strong focus on research and development in nations like the UK, France, and Germany. Favorable reimbursement and regulatory environments also contribute to the growth of the European IHC market.  

FAQs on the Immunohistochemistry (IHC) Market

1. What is Immunohistochemistry (IHC)?

2. What are the primary applications of IHC?

3. Why is IHC important in cancer diagnosis?

4. What are the main products used in IHC?

5. What are the latest advancements in the IHC market